IL-1 RII Antibody [Unconjugated]

Recombinant Human IL-1 RII (263-2R) inhibits Recombinant Human IL-1 beta /IL-1F2 (201-LB) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL-1 beta /IL-1F2 (50 pg/mL) activity elicited by Recombinant Human IL-1 RII (2 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-1 RII Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-263-NA). The ND50 is typically 15‑30 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-1 RII Antibody [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IL‑1 RII
  Phe14-Glu343 (Ser56Gly and Glu297Gly)
  Accession # P27930
• Specificity: Detects human IL‑1 RII in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross‑reactivity with recombinant human (rh) IL‑1 alpha , rhIL‑1 RI, recombinant mouse (rm) IL‑1 alpha , rhIL‑1 beta , rmIL‑1 beta , recombinant rat IL‑1 beta , rhIL‑1ra, rmIL‑1ra, and recombinant rhesus monkey IL‑1ra is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL1R2
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 15-30 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-1 RII Antibody [Unconjugated]

• beta
• CD121b antigen
• CD121b
• IL-1 R beta
• IL-1 RII
• IL1R2
• IL1RBCD121 antigen-like family member B
• IL-1R-beta
• IL1RII
• IL-1RII
• IL-1RT2
• IL-1RT-2
• interleukin 1 receptor, type II
• Interleukin-1 receptor beta
• MGC47725

Background

Two distinct types of receptors that bind the pleiotropic cytokines IL-1 alpha and IL-1 beta have been described. The IL-1 receptor type I is an 80 kDa transmembrane protein that is expressed predominantly by T cells, fibroblasts and endothelial cells. IL-1 receptor type II is a 68 kDa transmembrane protein found on B lymphocytes, neutrophils, monocytes, large granular leukocytes and endothelial cells. Both receptors are members of the immunoglobulin superfamily and show approximately 28% sequence similarity in their extracellular domains. The two receptor types do not heterodimerize in a receptor complex.

An IL-1 receptor accessory protein that can heterodimerize with the type I receptor in the presence of IL-1 alpha or IL-1 beta but not IL-1ra, was identified (1). This type I receptor complex appears to mediate all the known IL-1 biological responses. The receptor type II has a short cytoplasmic domain and does not transduce IL-1 signals. In addition to the membrane-bound form of IL-1 RII, a naturally-occurring soluble form of IL-1 RII has been described. It has been suggested that the type II receptor, either as the membrane-bound or as the soluble form, serves as a decoy for IL-1 and inhibits IL-1 action by blocking the binding of IL-1 to the signaling type I receptor complex. Recombinant IL-1 soluble receptor type II is a potent antagonist of IL-1 action.

1. Greenfeder, S. et al. (1995) J. Biol. Chem. 270:13757.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-1 RII Antibody (AF-263-NA)(6)

Publications using AF-263-NA

• M Yuan, L Wang, H Huang, Y Li, X Zheng, Q Shao, J Jiang IL-1R2 expression in human gastric cancer and its clinical significance Bioscience Reports, 2021-03-26;0(0):. 2021-03-26 [PMID: 33704402] (IHC, Human)
• GA Busslinger, BLA Weusten, A Bogte, H Begthel, LAA Brosens, H Clevers Human gastrointestinal epithelia of the esophagus, stomach, and duodenum resolved at single-cell resolution Cell Reports, 2021-03-09;34(10):108819. 2021-03-09 [PMID: 33691112] (IHC, Human)
• Chang SY, Su PF, Lee TC Ectopic expression of interleukin-1 receptor type II enhances cell migration through activation of the pre-interleukin 1alpha pathway. Cytokine, 2008-11-20;45(1):32-8. 2008-11-20 [PMID: 19026558] (ICC, Human)
• Herrmann-Lavoie C, Rao CV, Akoum A Chorionic gonadotropin down-regulates the expression of the decoy inhibitory interleukin 1 receptor type II in human endometrial epithelial cells. Endocrinology, 2007-08-16;148(11):5377-84. 2007-08-16 [PMID: 17702847] (Western Blot, Human)
• Kelley MJ, Rose AY, Song K, Chen Y, Bradley JM, Rookhuizen D, Acott TS Synergism of TNF and IL-1 in the induction of matrix metalloproteinase-3 in trabecular meshwork. Invest. Ophthalmol. Vis. Sci., 2007-06-01;48(6):2634-43. 2007-06-01 [PMID: 17525194] (Western Blot, Human)
• Estrogen’s bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells [PMID: 10330423] (Neutralization, Human)

Bioinformatics

• Gene Symbol: IL1R2
• Uniprot:
  • P27930()